🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the battle against increasingly resistant strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are increasing around the world, with data suggesting in excess of 82 million infections each year. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the reality of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Authorization

Zoliflodacin, also known as a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, was also approved in close succession. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Outcomes and Global Access

As per results published in a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The study included nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to register and commercialise the drug in many developing nations.

Medical professionals treating patients have voiced hope. Access to a single-dose, oral treatment like this is seen as a "critical tool" for managing the epidemic. This is viewed as vital to lessen the impact of the illness for individuals and to halt the transmission of untreatable gonorrhoea around the world.